Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBCBS Nebraska RFA and Transarterial Coverage Updat…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy M.55

    MA Radiofrequency Ablation or Transarterial Therapy for the Liver (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.55 alerts

    Get alerted when Policy M.55 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Preauthorization and coverage guidance for radiofrequency ablation (RFA) and arterially directed transarterial therapies (TAE, TACE, TARE) and related ablation techniques for hepatocellular carcinoma and liver metastases for Blue Cross Blue Shield - Nebraska members.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Radiofrequency Ablation or Transarterial Therapy for the Liver (Preauthorization Required)
    Policy CodePolicy M.55
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateNov 4, 2026
    Key ActionObtain preauthorization and reference MCG clinical criteria when submitting requests for RFA or transarterial liver therapies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Requiredpreauthorization required
    MCGexternal criteria
    7 codescodes listed
    Citedguideline refs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Medical necessity (referenced external criteria)

    Coverage decisions rely on external Milliman/MCG clinical criteria and established guideline literature to determine medical necessity for hepatic ablative and arterially directed therapies.

    Coverage determination sources: Use Milliman/MCG clinical criteria and cited guideline literature (e.g., ACR, NCCN, Lancet) to determine medical necessity for radiofrequency ablation, other ablative techniques, and transarterial therapies for liver tumors.

    The policy defers to MCG for specific eligibility criteria, appropriateness determinations, and detailed patient selection guidance.

    Coverage determinations for radiofrequency ablation and arterially directed transarterial therapies of the liver are made by applying the procedure codes listed in this policy together with external clinical guidance. Use the listed CPT codes (for example, 37242, 37243, 47370, 47380, 47382, 47383, 76940) in conjunction with the Milliman/MCG clinical criteria referenced by this policy to determine medical necessity and appropriateness for individual members. The policy explicitly directs reviewers to the MCG resources for specific eligibility and clinical decision rules.

    This policy does not enumerate discrete ‘‘not medically necessary’’ exclusions within the document text. Instead, determinations that a requested service is not medically necessary should be based on the MCG clinical criteria and applicable guideline literature cited by the policy, applied to the member’s clinical presentation and the specific CPT code(s) submitted.

    Covered Indications

    Hepatocellular carcinoma and liver metastases

    Covered when the treatment of hepatocellular carcinoma (HCC) or liver metastases is appropriate according to clinical guidelines and Milliman/MCG criteria.

    Indications overview: Management of hepatocellular carcinoma (HCC) and liver metastases with percutaneous, surgical, or image-guided ablative techniques (e.g., RFA, microwave, cryoablation, PEI, IRE) or arterially directed therapies (TAE, TACE, TARE/RE) when indicated by MCG and cited guideline literature.

    Refer to MCG and guideline references (ACR, NCCN, Lancet) for indication-level eligibility, staging considerations, and selection between modalities.

    Coding

    Covered CPT Codes (listed in policy)CPTCovered
    37242VASCULAR EMBOLIZATION OR OCCLUSION ARTERIAL RS&I
    37243VASCULAR EMBOLIZE/OCCLUDE ORGAN TUMOR INFARCT
    47370LAPS SURG ABLTJ 1/> LVR TUM RF
    47380ABLTJ OPN 1/> LVR TUM RF
    47382ABLTJ 1/> LVR TUM PRQ RF
    47383ABLATION 1/> LIVER TUMOR PERQ CRYOABLATION
    76940US &MNTR PARENCHYMAL TISSUE ABLATION

    Provider Actions

    Prior Authorization

    Preauthorization required for RFA and transarterial therapies

    Preauthorization is required for radiofrequency ablation and arterially directed transarterial therapies of the liver. Submit prior authorization requests using the payer's preauthorization process and reference MCG clinical criteria as applicable.

    • Applies to procedures listed in the policy (see CPT codes in policy).
    • Contact umanagement@p3hp.org for access to MCG if needed.
    Step Therapy

    No step therapy program specified

    This policy does not impose a step therapy program or a required stepwise treatment sequence. Appropriateness and eligibility are determined by referenced clinical criteria (Milliman/MCG) and guideline literature.

    Definitions

    Ablative techniques (definitions)
    DefinitionAblative techniques are methods that directly destroy tumor tissue using chemical, thermal, cryogenic, or high-voltage electrical mechanisms.
    Included modalitiesPercutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation, cryoablation, and irreversible electroporation (IRE).
    MechanismsChemical (ethanol injection causing cellular necrosis), thermal (heat from RFA or microwave to produce tumor injury), cryogenic (freezing with cold gases), and high-voltage electrical pulses (IRE increasing membrane permeability leading to cell death).
    Typical approachProbes or needles are placed into the tumor percutaneously under image guidance or surgically to deliver the ablative energy or agent.
    Clinical noteRFA has largely replaced PEI as the most widely used modality for HCC due to improved survival and lower recurrence, but PEI remains an option when thermal ablation is unsafe or technically difficult (e.g., proximity to biliary structures or other organs).

    Background

    Hepatocellular carcinoma (HCC) and liver metastases can be managed surgically or with locoregional therapies that induce tumor necrosis when resection is not feasible. Treatment options include surgical resection and percutaneous or surgical ablative approaches as well as catheter-directed, arterially delivered therapies. Ablative techniques encompass chemical methods (for example, percutaneous ethanol injection), thermal methods such as radiofrequency ablation and microwave ablation, cryoablation, and irreversible electroporation. Transarterial therapies include bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE) using yttrium-90 microspheres. These modalities are considered per clinical guideline recommendations and the Milliman/MCG criteria when selecting appropriate candidates for locoregional liver therapy.

    Prior Authorization

    Prior Authorization

    Preauthorization required prior to service for listed procedures

    All listed interventional ablation and transarterial procedures for the liver require preauthorization prior to the service being performed.

    • Covered procedures are those enumerated in the policy CPT list (e.g., 37242, 37243, 47370, 47380, 47382, 47383, 76940).
    • Preauthorization must be obtained before the service date.
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Radiofrequency Ablation or Transarterial Therapy for the Liver (Preauthorization Required)
    Policy CodePolicy M.55
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateNov 4, 2026
    Key ActionObtain preauthorization and reference MCG clinical criteria when submitting requests for RFA or transarterial liver therapies.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider ActionsDefinitionsBackgroundPrior Authorization
    Documentation Required

    Reference MCG criteria and include listed CPT codes

    Preauthorization requests should reference the Milliman/MCG clinical criteria and include the relevant procedure CPT codes as listed in the policy.

    • Example CPT codes to include: 37242, 37243, 47370, 47380, 47382, 47383, 76940.
    • If you need MCG access or criteria, contact umanagement@p3hp.org.
    Denial Risk

    Risk of denial if procedure submitted without paired diagnosis or proper code-pair

    Procedures submitted without an associated diagnosis code or without using the policy's Quick Code Search code-pair process may be at risk for denial or held for review.

    • Use the Quick Code Search to add a procedure + diagnosis code pair before submission.
    • Enter at least the first three characters of the procedure and diagnosis codes when using the Quick Code Search.
    Transarterial therapy (definitions)
    DefinitionTransarterial therapies are catheter-directed arterial treatments that embolize the tumor blood supply or deliver chemotherapy or radiation directly to the tumor.
    Included proceduresTransarterial bland embolization (TAE), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE or RE with yttrium-90 microspheres).
    Mechanism of actionEmbolization blocks arterial blood flow to the tumor; chemotherapy or radiation can be delivered via the catheter to concentrate cytotoxic effects and reduce systemic exposure.
    Delivery methodProcedures are performed by placing a catheter in the hepatic artery to target hypervascular hepatic tumors which primarily receive blood from the hepatic artery.
    Clinical rationaleThese therapies exploit the hepatic tumor’s arterial blood supply to induce tumor necrosis while limiting systemic toxicity of chemo- or radiotherapy.